Kurt C. Wheeler is an Operating Partner in the Blackstone Life Sciences group and a member of its Investment Committee, having joined Blackstone as part of its acquisition of Clarus in December 2018. Prior to joining Blackstone, Mr. Wheeler was a co-founder and Managing Director of Clarus since the firm's inception in 2005.

Mr. Wheeler has over 30 years of direct investment and industry operating experience within the healthcare sector where he has led investments in the medical technology, specialty pharmaceutical, and biotechnology space including partnerships with pharmaceutical companies. Prior to Clarus, Mr. Wheeler was a General Partner at MPM Capital, a healthcare venture capital firm. Mr. Wheeler was a co-founder and CEO of InControl, a medical device company which he sold to Guidant.

Mr. Wheeler holds a BA from Brigham Young University and an MBA from Northwestern University's Kellogg School.